GlassScriptPhysician profile
Amit B Mehta
NPI 1811175003
$3,434.83
in general payments reported to CMS, 2019-2025
35 companies · $203 in 2025
The $203 reported for 2025 was more than what 81% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $384 · 2021: $718 · 2022: $284 · 2023: $326 · 2024: $149 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $602.80 | 2019-2020 | |
| Nalu Medical, INC. | $306.91 | 2021-2025 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $230.67 | 2019-2021 | |
| Abbott Laboratories | $203.72 | 2021-2024 | Proclaim, Ionicrf |
| Abbvie INC. | $191.29 | 2021-2025 | |
| Foundation Fusion Solutions, LLC | $170.84 | 2023 | |
| Lilly USA, LLC | $169.18 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.79 | 2019-2021 | |
| Pfizer INC. | $140.60 | 2019-2024 | |
| Sentynl Therapeutics, INC. | $133.22 | 2019-2020 | |
| Nevro Corp. | $124.77 | 2019-2021 | |
| Boston Scientific Corporation | $107.11 | 2019-2021 | |
| Tersera Therapeutics LLC | $103.13 | 2019 | |
| Medtronic, INC. | $92.83 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $74.03 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $70.07 | 2021 | |
| Allergan, INC. | $66.68 | 2019-2021 | |
| Painteq LLC | $64.01 | 2025 | Painteq |
| Pacira Pharmaceuticals Incorporated | $38.88 | 2024 | Iovera, Zilretta |
| Fidia Pharma USA INC. | $37.97 | 2019-2020 | |
| Daiichi Sankyo INC. | $34.49 | 2019 | |
| Ibsa Pharma INC. | $34.01 | 2020-2021 | |
| Lundbeck LLC | $30.68 | 2022 | |
| Scilex Pharmaceuticals INC. | $29.25 | 2019 | |
| Zyla Life Sciences, INC. | $28.79 | 2019 | |
| Si-Bone, INC. | $25.16 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.63 | 2024 | Strensiq |
| Redhill Biopharma INC. | $23.41 | 2020 | |
| Trevena, INC. | $22.31 | 2023 | Olinvyk |
| Biodelivery Sciences International, INC. | $17.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.55 | 2020 | |
| Curonix LLC | $15.80 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Novartis Pharmaceuticals Corporation | $14.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.53 | 2019 | |
| Hikma Pharmaceuticals USA | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.